Karyopharm Therapeutics
KPTI
85 hedge funds and large institutions have $637M invested in Karyopharm Therapeutics in 2015 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 49 increasing their positions, 14 reducing their positions, and 11 closing their positions.
250% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 14
36% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 11
5% more funds holding
Funds holding: 81 → 85 (+4)
9% less capital invested
Capital invested by funds: $702M → $637M (-$64.5M)
39% less call options, than puts
Call options by funds: $2.76M | Put options by funds: $4.52M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$27.3M |
| 2 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$9.75M |
| 3 |
State Street
Boston,
Massachusetts
|
+$9.01M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.88M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$7.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management I
Larkspur,
California
|
-$37.4M |
| 2 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$9.44M |
| 3 |
BG
BlackRock Group
London,
United Kingdom
|
-$7.86M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$3.03M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$2.8M |
KPTI Hedge Fund Activity: Q1 2015 in Review
85 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q1 2015, worth a combined $637M — down 9.2% from $702M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new KPTI positions and 11 closed out — a net gain of 4 holders — while 49 added to existing stakes and 14 trimmed.
The largest buyer was Palo Alto Investors, opening a new position worth an estimated $27.3M. The largest seller was Foresite Capital Management I, exiting entirely with an estimated $37.4M sold.
- 85 institutional investors held Karyopharm Therapeutics (KPTI) as of Q1 2015, up from 81 in Q4 2014.
- Funds reported $637M of Karyopharm Therapeutics stock for Q1 2015, down 9.2% quarter-over-quarter.
- 15 funds opened new Karyopharm Therapeutics positions in Q1 2015 and 11 closed out, a net change of +4 holders.
- The largest Karyopharm Therapeutics buyer in Q1 2015 was Palo Alto Investors, an estimated $27.3M added.
- The largest Karyopharm Therapeutics seller in Q1 2015 was Foresite Capital Management I, an estimated $37.4M sold.
Based on aggregated 13F filings for Q1 2015.